Interpretation of Expert consensus on Shujin Jianyao Pills in clinical practice.
10.19540/j.cnki.cjcmm.20200229.502
- Author:
Huan LIU
1
;
Jing-Hua GAO
2
;
Yan-Ming XIE
1
;
Yuan-Yuan LI
1
;
Sheng-Hua LI
3
;
Ling ZHANG
4
;
Zu-Jian XU
5
;
Feng HUANG
6
;
Jin JIN
7
;
Gang LI
8
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.
3. Gansu Provincial Hospital of Traditional Chinese Medicine Lanzhou 730050, China.
4. School of Public Health, Capital Medical University Beijing 100069, China.
5. Traditional Chinese Medicine Hospital Affiliated to South-East Medical University Luzhou 646000, China.
6. the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510405, China.
7. Peking Union Medical College Hospital Beijing 100730, China.
8. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Ji'nan 250014, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent drug;
Shujin Jianyao Pills;
evidence-based medicine;
expert consensus;
interpretation;
traditional Chinese medicine
- MeSH:
China;
Consensus;
Drugs, Chinese Herbal;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2020;45(14):3336-3339
- CountryChina
- Language:Chinese
-
Abstract:
Shujin Jianyao Pills is a kind of concentrated honey pills made of 13 Chinese herbal medicines, such as Cibotii Rhizoma, Rosae Laevigatae Fructus, and Spatholobi Caulis. It has the effects in tonifying liver and kidney, strengthening muscles and bones, removing wind and dampness, activating collaterals and relieving pain. Under the leadership of the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences and Wangjing Hospital of China Academy of Chinese Medical Sciences, the Expert consensus on clinical application of Shujin Jianyao Pills was developed by 22 universities, scientific research institutes and hospitals. This consensus formed 1 recommendation and 9 consensus suggestions, which were based on evidence and oriented to clinical practice. The expert consensus had a new understanding of the indications of Shujin Jianyao Pills, especially the applicable Western medicine diseases, the advantages and characteristics of treatment, the time of intervention, the applicable syndromes, the precautions and contraindications of medication. The indications were detailed and expressed as the combination of disease, symptom and syndrome. And it filled in the gaps of package inserts in applicable syndrome and special population medication in the process of drug use. The expert consensus showed the optimization of precautions and contraindications, and more detailed description of drug safety. Therefore, it provides guidance and reference for clinicians to use Shujin Jianyao Pills rationally.
